Although at this point no IGF-1R inhibiting substance has been approved for clinical use due to severe side effects, we also investigated the IGF-1R inhibitor AEW541 since its cytotoxic activity has been proven in several in vitro analyses, e.g. in Ewing’s sarcoma, multiple myeloma and gastrointestinal stromal tumors and we could not find any data concerning IGR-1R expression in TGCTs [30,61,62]. The gene discussed is IGF1R; the disease is plasma cell myeloma.